Immunapherese mit Doppeladsorbern – Viele Einsatzmöglichkeiten und hohe Leistung

• Literatur

• 1 Belàk M, Borberg H, Jimenez C, Oette K. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994; 15: 419-422
• 2 Gjörstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfus Sci 1990; 11: 281-302
• 3 Staudt A, Dörr M, Staudt Y et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005; 150: 729-736
• 4 Schmaldienst S, Müllner M, Goldammer A et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?. Rheumatology (Oxford) 2001; 40: 513-521
• 5 Braun N. Fundamentals and Applications of Immunoadsorption. 1st ed. Bremen: UNI-MED; 2009
• 6 Doesch AO, Konstandin M, Celik S et al. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. J Clin Apher 2009; 24: 141-149
• 7 Freedman J, Rand ML, Russell O et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: 1508-1513
• 8 Négrier C, Dechavanne M, Alfonsi F, Tremisi PJ. Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption. Acta Haematol 1991; 85: 107-110
• 9 Kasper S, Neurath M, Huber C et al. Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy. Transfusion 2007; 47: 1263-1267
• 10 Borghardt EJ, Kirchertz EJ, Marten I, Fenchel K. Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transfus Sci 1998; (Suppl. 19) 5-7
• 11 Schwenger V, Morath C. Immunoadsorption in Nephrology and Kidney Transplantation. Nephrol Dial Transplant 2010; 25: 2407-2413
• 12 Ruiz JC, Berciano J, Polo JM et al. Treatment of Guillain-Barré syndrome with protein-A immunoadsorption: report of two cases. Ann Neurol 1992; 31: 574-575
• 13 Rech J, Hueber AJ, Kallert S et al. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Ther Apher Dial 2008; 12: 205-208
• 14 Schneidewind JM, Winkler R, Ramlow W et al. Immunoadsorption a new therapeutic possibility for multiple sclerosis?. Transfus Sci 1998; (Suppl. 19) 59-63
• 15 Antozzi C, Frassoni C, Vincent A et al. Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia. Neurology 2005; 64: 1290-1293
• 16 Braun N. Plasmapherese und verwandte Verfahren zur Behandlung des systemischen Lupus erythematodes. Nieren- und Hochdruckkrankh 2005; 64: 1290-1293
• 17 Koch M, Kohnle M, Trapp R. A case report of successful long-term relapse control by protein-A immunoadsorption in an immunosuppressive-treated patient with end-stage renal disease due to Wegener‘s granulomatosis. Ther Apher Dial 2009; 13: 150-156
• 18 Matic G, Bosch T, Ramlow W. Background and Indications for Protein A-Based Extracorporeal Immunoadsorption. Ther Apher 2001; 5: 394-403
• 19 Wahrmann M, Exner M, Schillinger M et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6: 1-5
• 20 Böhmig GA, Wahrmann M, Regele H et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117-121
• 21 Lorenz M, Regele H, Schillinger M et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696-701
• 22 Bartel G, Wahrmann M, Regele H et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033-2042
• 23 Moriconi L, Lenti C, Puccini R et al. Proteinuria in focal segmental glomerulosclerosis: role of circulating factors and therapeutic approach. Ren Fail 2001; 23: 533-541